New antibody drug may restore skin color in vitiligo patients

NCT ID NCT07223229

Recruiting now Disease control Sponsor: Elixiron Immunotherapeutics (Hong Kong) Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 24 times

Summary

This study tests whether a new drug called EI-001 can help people with nonsegmental vitiligo regain skin color. The drug works by calming the immune system to reduce inflammation that causes white patches. About 45 adults aged 18-65 with vitiligo for at least 3 months will receive either the drug or a placebo. The main goal is to see if the drug improves skin repigmentation safely.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SEGMENTAL VITILIGO are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Linkou Chang Gung Memorial Hospital
RECRUITING

Taoyuan, Taiwan

Contact Phone: •••-•••-•••• Email: •••••@•••••
Skin Care Research, LLC
NOT_YET_RECRUITING

Hollywood, Florida, 33021, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
U Mass Chan Medical School
WITHDRAWN

Worcester, Massachusetts, 01605, United States

Conditions

Explore the condition pages connected to this study.

NON-SEGMENTAL VITILIGO